Fiche publication
Date publication
janvier 2013
Journal
The Lancet. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
,
Pr BOUCHE Olivier
Tous les auteurs :
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S,
Lien Pubmed
Résumé
Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and bevacizumab-naive second-line metastatic colorectal cancer. We assessed continued use of bevacizumab plus standard second-line chemotherapy in patients with metastatic colorectal cancer progressing after standard first-line bevacizumab-based treatment.
Mots clés
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Bevacizumab, Colorectal Neoplasms, drug therapy, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, drug therapy, Vascular Endothelial Growth Factor A, antagonists & inhibitors
Référence
Lancet Oncol.. 2013 Jan;14(1):29-37
